“Retinitis Pigmentosa Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Retinitis Pigmentosa Market.
The Retinitis Pigmentosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Retinitis Pigmentosa Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Retinitis Pigmentosa and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Retinitis Pigmentosa market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Retinitis Pigmentosa – Emerging Therapies Mechanism of Action (MOA)
-
Gene transference
-
Cell replacements
-
Integrin inhibitors
-
Cell replacements; Nerve growth factor modulators
Retinitis Pigmentosa – Route of Administration
Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
Molecule Type
Products have been categorized under various Molecule types, such as –
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the Retinitis Pigmentosa Therapeutic Segment @ https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight
Retinitis Pigmentosa Therapeutics Landscape
Currently, there is no therapy that can stop the evolution of pigmentary retinopathies or restore vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery, etc. Gene therapy-based treatments are under research focus for the treatment of Retinitis pigmentosa.
There are approx. 45+ key companies developing therapies for Retinitis Pigmentosa. Currently, Biogen is leading the therapeutics domain with its Retinitis Pigmentosa drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Retinitis Pigmentosa Therapeutics Market Include:
-
Allegro Ophthalmics
-
Allergan
-
Biogen
-
Dompé Farmaceutici
-
Editas Medicine
-
Horama
-
ID Pharma
-
Ionis Pharmaceuticals
-
jCyte
-
MeiraGTx
-
Nacuity Pharmaceuticals
-
Neurotech
-
Nightstar Therapeutics/Biogen
-
Novartis Pharmaceuticals
-
OiDE OptoEye
-
ReNeuron
-
ReNeuron
-
Sanofi (Terminated)
-
SparingVision
And Many Others
Retinitis Pigmentosa Drugs Covered in the Report Include:
-
BIIB-112: Biogen
-
QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
-
ALG-1001: Allegro Ophthalmics/Hanmi Pharmaceuticals
-
NPI 001: Nacuity Pharmaceuticals
-
AAV8- RPGR/BIIB1121: Nightstar Therapeutics/Biogen
-
ReN 003: ReNeuron
-
jCell: jCyte
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Retinitis Pigmentosa Current Treatment Patterns
4. Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Retinitis Pigmentosa Late Stage Products (Phase-III)
7. Retinitis Pigmentosa Mid-Stage Products (Phase-II)
8. Retinitis Pigmentosa Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Retinitis Pigmentosa Discontinued Products
13. Retinitis Pigmentosa Product Profiles
14. Key Companies in the Retinitis Pigmentosa Market
15. Key Products in the Retinitis Pigmentosa Therapeutics Segment
16. Dormant and Discontinued Products
17. Retinitis Pigmentosa Unmet Needs
18. Retinitis Pigmentosa Future Perspectives
19. Retinitis Pigmentosa Analyst Review
20. Appendix
21. Report Methodology
Download Sample PDF to Explore the Key Offerings of the Report: https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/